Biotechnology company developing a discovery platform to engage the immune system’s pro-resolution responses and restore immune balance in chronic inflammatory and autoimmune disorders, aiming to avoid broad immunosuppression
Biotechnology company developing a discovery platform to engage the immune system’s pro-resolution responses and restore immune balance in chronic inflammatory and autoimmune disorders, aiming to avoid broad immunosuppression. Its approach is based on a defined myeloid cell state with suppressive functions and uses translatable biomarkers to validate and adjust therapeutic strategies in patients. Created through a collaboration between Johnson & Johnson Innovation, JJDC, and General Inception.